Curcumin reverses oxaliplatin resistance in human colorectal cancer via regulation of TGF-β/Smad2/3 signaling pathway
Authors Yin J, Wang L, Wang Y, Shen H, Wang X, Wu L
Received 26 December 2018
Accepted for publication 11 April 2019
Published 17 May 2019 Volume 2019:12 Pages 3893—3903
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Jyoti Bajaj
Peer reviewer comments 2
Editor who approved publication: Dr Gaetano Romano
Jiahuan Yin,1,* Li Wang,2,* Yong Wang,1 Hailong Shen,1 Xiaojie Wang,1 Lei Wu1
1Department of General Surgery, Shanghai Luodian Hospital, Shanghai 201908, People’s Republic of China; 2Department of Gynaecology and Obstetrics, Shanghai Luodian Hospital, Shanghai 201908, People’s Republic of China
*These authors contributed equally to this work
Background: Oxaliplatin (OXA) resistance is a main obstacle to the chemotherapy of colorectal cancer (CRC). Epithelial-mesenchymal transition (EMT), which is mainly regulated by TGF-β/Smad signaling pathway, has gradually been recognized as an important mechanism for tumor chemoresistance. Studies have shown that curcumin regulated EMT processes in many human cancers. However, whether curcumin could regulate OXA resistance in CRC through modulating TGF-β/Smad signaling-mediated EMT remains unclear.
Methods: In an attempt to investigate the effect of curcumin on OXA resistance in CRC, OXA-resistant cell line HCT116/OXA was established firstly. The effect of curcumin on cell proliferation was evaluated by MTT assay and Ki67 immunofluorescence staining, respectively. Cell apoptosis was evaluated by flow cytometry. In addition, transwell assay was used to detect the effect of curcumin on cell invasion and the activation of TGF-β/Smad signaling was examined by immunofluorescence and Western blot. Moreover, the therapeutic potential of curcumin was further examined in vivo using a CRC animal model.
Results: The OXA-resistant cell line HCT116/OXA was successfully established, and combination of OXA with curcumin reduced OXA resistance in vitro. Besides, the combination treatment inhibited the expressions of p-p65 and Bcl-2, but increased the level of active-caspase3. In addition, curcumin inhibited EMT via regulation of TGF-β/Smad2/3 signaling pathway. Moreover, in vivo study confirmed curcumin could reverse OXA resistance in CRC.
Conclusion: Our study indicated that curcumin could reserve OXA resistance in CRC through dampening TGF-β/Smads signaling in vitro and in vivo.
Keywords: colorectal cancer, oxaliplatin resistance, curcumin, epithelial-mesenchymal transition, TGF-β/Smad signaling pathway
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]